Cargando…
Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis
Psoriasis is a complex inflammatory disease that occurs in genetically susceptible individuals and presents with the development of erythematous scaly plaques on the skin. Interleukins (ILs) in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for rec...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363145/ https://www.ncbi.nlm.nih.gov/pubmed/28400641 http://dx.doi.org/10.4103/ijd.IJD_233_16 |